

Abstract

A method for treating human tumours by gene therapy is disclosed. In particular, defective recombinant viruses with a sequence coding for a human tumour-specific antigen, and the use thereof for treating or preventing human tumours, as well as producing specific cytotoxic T-cells (CTLs) in vitro or ex vivo, are disclosed. Pharmaceutical compositions comprising said viruses, particularly in injectable form, are also disclosed.